electroCore announces distribution agreement with Reliefband

electroCore announced that Reletex by Reliefband, the first and only FDA cleared non-invasive neuromodulation device available by prescription for nausea and vomiting, will be distributed and billed exclusively by electroCore within the Department of Veterans Affairs and other Federal Supply Schedule eligible entities. “We are thrilled to be offering the Reletex product within VA hospitals and other FSS eligible entities,” commented Dan Goldberger, Chief Executive Officer of electroCore. “We continue to build out our commercial sales organization and look for unique and complementary therapies which can be made available to our customer base. The drug-free, patient-controlled Reletex product is ideal for veterans suffering from nausea and vomiting and we believe it will be well adopted by customers who utilize neuromodulation devices such as our existing gammaCore(TM) therapy to treat medical conditions.